Phathom Pharmaceuticals Inc Ordinary shares PHAT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Phathom Pharmaceuticals to Participate in November Investor Conferences
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Trading Information
- Previous Close Price
- $5.45
- Day Range
- $5.40–6.19
- 52-Week Range
- $5.02–18.30
- Bid/Ask
- $6.03 / $6.10
- Shares Outstanding
- 81.29M
- Market Cap
- $492.63M
- Volume/Avg
- 413,712 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.61
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 371
Valuation
Metric | PHAT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.61 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | PHAT |
|---|---|
Quick Ratio | 1.67 |
Current Ratio | 1.76 |
Interest Coverage | −0.42 |
Quick Ratio
PHAT
Profitability
Metric | PHAT |
|---|---|
Return on Assets (Normalized) | −5.95% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PHAT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|<fb^>&r | LOCK|B%%L | $139B | |||
| Moderna Inc MRNA | LOCK|NLs$KZ | LOCK|^Yg | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|g#v<GB | LOCK|&#^K | $95B | |||
| argenx SE ADR ARGX | LOCK|!@zkmV% | LOCK|@!s | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|#z$%&#! | LOCK|$Y | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|q@s>ZYnH | LOCK|j!Q$$ | $31B | |||
| Incyte Corp INCY | LOCK|?P!#LDT | LOCK|^v | $25B | |||
| BioNTech SE ADR BNTX | LOCK|GS?jL? | LOCK|<%^ | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^P><C% | LOCK|bV&z | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|ngzW!D | LOCK|^Gp | $16B |
United States